RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
肿瘤细胞治疗研究
英文原题:Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺癌(PC)是一种高度恶性的肿瘤,近年来发病率不断上升。由于其起病隐匿、病理生理机制不明且预后较差,即便采用手术、放疗、生物治疗和靶向治疗等多种方法,患者总生存率仍未明显改善。因此,开发更安全、有效的胰腺癌治疗方法至关重要。近年来,细胞免疫疗法在肿瘤学领域取得显著进展,技术不断发展,几乎每月都有新突破,胰腺癌治疗效果有望进一步改善。本文探讨嵌合抗原受体NK 细胞(CAR-NK)免疫疗法在胰腺癌研究中的进展,并介绍胰腺癌治疗的研究思路。
Pancreatic cancer (PC) is a highly malignant tumor with an increasing incidence rate in recent years. Because pancreatic cancer has an insidious onset, unknown pathophysiology, and poor prognosis, the overall survival rate of pancreatic cancer patients has not improved considerably even with extensive treatment methods such as surgery, radiation, biotherapy, and targeted therapy.
Therefore, finding and developing more effective and safe treatments for pancreatic cancer is critical. Cellular immunotherapy has achieved considerable advances in the field of oncology in recent years.
Technology is continuously advancing, with new breakthroughs virtually every month, and pancreatic cancer eradication is expected to improve considerably. This article examines the advance of chimeric antigen receptor NK cell immunotherapy (CAR-NK) cell immunotherapy for pancreatic cancer research, as well as research ideas for pancreatic cancer treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。